This site is intended for healthcare professionals
FDA Hero  Banner - Multi-coloured pills and tablets
FDA Drug information

Famotidine

Read time: 1 mins
Marketing start date: 07 May 2024

Summary of product characteristics


Effective Time

20220826

Version

2

Spl Product Data Elements

Famotidine Famotidine FAMOTIDINE FAMOTIDINE HYPROMELLOSE 2910 (5 MPA.S) HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE 101 MICROCRYSTALLINE CELLULOSE 102 POLYETHYLENE GLYCOL 8000 SILICON DIOXIDE SODIUM STARCH GLYCOLATE TYPE A STARCH, CORN TALC TITANIUM DIOXIDE off white Z21 Famotidine Famotidine FAMOTIDINE FAMOTIDINE HYPROMELLOSE 2910 (5 MPA.S) HYPROMELLOSE 2910 (6 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE 101 MICROCRYSTALLINE CELLULOSE 102 POLYETHYLENE GLYCOL 8000 SILICON DIOXIDE SODIUM STARCH GLYCOLATE TYPE A STARCH, CORN TALC TITANIUM DIOXIDE off white Z41

Application Number

ANDA216441

Brand Name

Famotidine

Generic Name

Famotidine

Product Ndc

70771-1702

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1702-3 Famotidine Tablets USP, 20 mg 30 Tablets Rx only NDC 70771-1703-3 Famotidine Tablets USP, 40 mg 30 Tablets Rx only 20 mg label 40 mg label

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.